Related Experiment Video
Updated: Jun 13, 2026
03:45
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy
Libin Wang1, Jonathan G Seidman, Christine E Seidman
1Harvard Medical School and Howard Hughes Medical Institute, Boston, Massachusetts, USA.
Annals of Internal Medicine
|April 21, 2010
Summary
Genetic insights into hypertrophic cardiomyopathy (HCM) are revolutionizing diagnosis and treatment. Identifying sarcomere protein mutations allows for early risk identification and development of novel therapies for this common heart muscle disorder.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is characterized by unexplained cardiac hypertrophy, affecting 1 in 500 adults.
- HCM is a common myocardial disorder with significant clinical implications.
Purpose of the Study:
- To review the impact of genetic discoveries on understanding and managing hypertrophic cardiomyopathy.
- To highlight the role of genetic diagnostics and emerging therapies in altering the disease's natural history.
Main Methods:
- Review of human genetic studies identifying mutations in sarcomere proteins as causative for HCM.
- Analysis of mechanistic investigations in model organisms engineered with human HCM mutations.
- Assessment of current clinical trials for novel therapeutic targets.
Main Results:
- Dominant mutations in sarcomere proteins are established genetic causes of HCM.
- Clinical gene-based diagnostics enable precise mutation identification and preclinical risk assessment in families.
- Mechanistic studies have identified novel therapeutic targets currently under clinical evaluation.
Conclusions:
- Genetic discoveries are fundamentally reshaping the diagnosis and treatment paradigms for HCM.
- Gene-based diagnostics and new therapeutic strategies offer hope for changing the lifelong course of HCM.
- Integrated approaches combining genetic insights with novel therapies are improving outcomes for patients with HCM.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:25Cardiomyopathy I: Introduction and Classification
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...